A new trading day began on Friday, with Xeris Biopharma Holdings Inc (NASDAQ: XERS) stock price down -5.91% from the previous day of trading, before settling in for the closing price of $2.03. XERS’s price has ranged from $1.46 to $3.26 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 195.35% over the past five years. Meanwhile, its annual earnings per share averaged 23.17%. With a float of $125.56 million, this company’s outstanding shares have now reached $138.13 million.
Let’s look at the performance matrix of the company that is accounted for 377 employees.
Xeris Biopharma Holdings Inc (XERS) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Xeris Biopharma Holdings Inc is 10.60%, while institutional ownership is 41.15%. The most recent insider transaction that took place on Mar 14 ’24, was worth 9,720. In this transaction Director of this company bought 4,500 shares at a rate of $2.16, taking the stock ownership to the 11,000 shares. Before that another transaction happened on Nov 27 ’23, when Company’s Director bought 5,400 for $1.87, making the entire transaction worth $10,098. This insider now owns 5,400 shares in total.
Xeris Biopharma Holdings Inc (XERS) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of 1.75 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 23.17% per share during the next fiscal year.
Xeris Biopharma Holdings Inc (NASDAQ: XERS) Trading Performance Indicators
Here are Xeris Biopharma Holdings Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 1.23. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.64.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.45, a number that is poised to hit -0.11 in the next quarter and is forecasted to reach -0.15 in one year’s time.
Technical Analysis of Xeris Biopharma Holdings Inc (XERS)
Xeris Biopharma Holdings Inc (NASDAQ: XERS) saw its 5-day average volume 1.39 million, a negative change from its year-to-date volume of 2.22 million. As of the previous 9 days, the stock’s Stochastic %D was 20.09%. Additionally, its Average True Range was 0.12.
During the past 100 days, Xeris Biopharma Holdings Inc’s (XERS) raw stochastic average was set at 21.91%, which indicates a significant increase from 9.76% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 48.79% in the past 14 days, which was lower than the 76.31% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.5069, while its 200-day Moving Average is $2.2317. Nevertheless, the first resistance level for the watch stands at $2.0133 in the near term. At $2.1167, the stock is likely to face the second major resistance level. The third major resistance level sits at $2.1883. If the price goes on to break the first support level at $1.8383, it is likely to go to the next support level at $1.7667. The third support level lies at $1.6633 if the price breaches the second support level.
Xeris Biopharma Holdings Inc (NASDAQ: XERS) Key Stats
With a market capitalization of 268.26 million, the company has a total of 140,453K Shares Outstanding. Currently, annual sales are 163,910 K while annual income is -62,260 K. The company’s previous quarter sales were 44,390 K while its latest quarter income was -13,390 K.
